CD39 abrogates platelet-derived factors induced IL-1β expression in the human placenta.
adenosine triphosphate (ATP)
ectonucleotidases
placenta
platelet-derived factors
preecclampsia
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2023
accepted:
16
05
2023
medline:
16
6
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
epublish
Résumé
Tissue insults in response to inflammation, hypoxia and ischemia are accompanied by the release of ATP into the extracellular space. There, ATP modulates several pathological processes, including chemotaxis, inflammasome induction and platelet activation. ATP hydrolysis is significantly enhanced in human pregnancy, suggesting that increased conversion of extracellular ATP is an important anti-inflammatory process in preventing exaggerated inflammation, platelet activation and hemostasis in gestation. Extracellular ATP is converted into AMP, and subsequently into adenosine by the two major nucleotide-metabolizing enzymes CD39 and CD73. Here, we aimed to elucidate developmental changes of placental CD39 and CD73 over gestation, compared their expression in placental tissue from patients with preeclampsia and healthy controls, and analyzed their regulation in response to platelet-derived factors and different oxygen conditions in placental explants as well as the trophoblast cell line BeWo. Linear regression analysis showed a significant increase in placental CD39 expression, while at the same time CD73 levels declined at term of pregnancy. Neither maternal smoking during first trimester, fetal sex, maternal age, nor maternal BMI revealed any effects on placental CD39 and CD73 expression. Immunohistochemistry detected both, CD39 and CD73, predominantly in the syncytiotrophoblast layer. Placental CD39 and CD73 expression were significantly increased in pregnancies complicated with preeclampsia, when compared to controls. Cultivation of placental explants under different oxygen conditions had no effect on the ectonucleotidases, whereas presence of platelet releasate from pregnant women led to deregulated CD39 expression. Overexpression of recombinant human CD39 in BeWo cells decreased extracellular ATP levels after culture in presence of platelet-derived factors. Moreover, platelet-derived factors-induced upregulation of the pro-inflammatory cytokine, interleukin-1β, was abolished by CD39 overexpression. Our study shows that placental CD39 is upregulated in preeclampsia, suggesting an increasing demand for extracellular ATP hydrolysis at the utero-placental interface. Increased placental CD39 in response to platelet-derived factors may lead to enhanced conversion of extracellular ATP levels, which in turn could represent an important anti-coagulant defense mechanism of the placenta.
Identifiants
pubmed: 37325567
doi: 10.3389/fcell.2023.1183793
pii: 1183793
pmc: PMC10264854
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1183793Informations de copyright
Copyright © 2023 Forstner, Guettler, Brugger, Lyssy, Neuper, Daxboeck, Cvirn, Fuchs, Kraeker, Frolova, Valdes, Stern, Hirschmugl, Fluhr, Wadsack, Huppertz, Nonn, Herse and Gauster.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Gynecol Obstet Invest. 2002;54(3):164-7
pubmed: 12571439
Blood. 2021 Feb 18;137(7):977-982
pubmed: 32870264
Obstet Gynecol. 2005 Jan;105(1):129-38
pubmed: 15625154
Circulation. 2015 Feb 24;131(8):730-41
pubmed: 25538227
Eur J Histochem. 2004 Jul-Sep;48(3):253-9
pubmed: 15590415
Placenta. 2000 Mar-Apr;21(2-3):133-41
pubmed: 10736235
Tissue Antigens. 1990 Jan;35(1):9-19
pubmed: 2137649
Blood. 2016 Oct 27;128(17):2153-2164
pubmed: 27589872
Nephrol Dial Transplant. 2010 Aug;25(8):2468-78
pubmed: 20223894
Hypertens Pregnancy. 2007;26(2):227-39
pubmed: 17469012
Hypertension. 2016 Jul;68(1):137-47
pubmed: 27160201
J Reprod Immunol. 2021 Apr;144:103280
pubmed: 33530024
Front Immunol. 2017 Jun 22;8:727
pubmed: 28690614
Thromb Res. 2017 Mar;151 Suppl 1:S30-S33
pubmed: 28262230
Cells. 2021 Aug 27;10(9):
pubmed: 34571872
Purinergic Signal. 2022 Dec;18(4):409-419
pubmed: 35947229
Int J Mol Sci. 2019 Feb 02;20(3):
pubmed: 30717334
Int J Mol Sci. 2020 Jan 22;21(3):
pubmed: 31979196
Front Pharmacol. 2018 Apr 20;9:196
pubmed: 29731713
Differentiation. 2008 Dec;76(10):1031-43
pubmed: 18673379
Cell Mol Neurobiol. 2022 Aug;42(6):1965-1981
pubmed: 33761054
Placenta. 2005 Jul;26(6):439-48
pubmed: 15950058
Circulation. 2012 Dec 18;126(25):2990-9
pubmed: 23155181
J Mol Med (Berl). 2020 Feb;98(2):193-207
pubmed: 31863152
Pregnancy Hypertens. 2018 Oct;14:59-67
pubmed: 30527120
Life Sci. 2020 Oct 15;259:118389
pubmed: 32898522
Sci Signal. 2021 Mar 02;14(672):
pubmed: 33653920
EMBO J. 1998 Jun 1;17(11):3091-100
pubmed: 9606191
Hypertension. 2021 May 5;77(5):1723-1736
pubmed: 33775117
Lab Invest. 2017 Apr;97(4):409-418
pubmed: 28112754
Obstet Gynecol. 2002 Dec;100(6):1266-70
pubmed: 12468172
J Mol Med (Berl). 2022 Apr;100(4):645-663
pubmed: 35249135
Curr Atheroscler Rep. 2014 Jul;16(7):425
pubmed: 24838375
Blood Cells Mol Dis. 2006 Mar-Apr;36(2):217-22
pubmed: 16476557
Biomedicines. 2022 Aug 10;10(8):
pubmed: 36009485
Placenta. 2012 Nov;33(11):952-4
pubmed: 23026742
Placenta. 2009 May;30(5):434-42
pubmed: 19303140
Hypertension. 2014 Jun;63(6):1154-60
pubmed: 24688119
Histochem Cell Biol. 2012 May;137(5):641-55
pubmed: 22294260
Pregnancy Hypertens. 2018 Jul;13:291-310
pubmed: 29803330
Blood. 2009 Jan 1;113(1):224-32
pubmed: 18812468
J Obstet Gynaecol Res. 2008 Aug;34(4):487-93
pubmed: 18937701
Pharmacol Ther. 2009 Jul;123(1):105-16
pubmed: 19426761
Eur Respir J. 2016 Jan;47(1):254-63
pubmed: 26541524
Circulation. 2007 Oct 16;116(16):1784-94
pubmed: 17909107
Circ Res. 2004 Oct 15;95(8):814-21
pubmed: 15358667
Lab Invest. 2023 May;103(5):100059
pubmed: 36801640
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700
Oncoimmunology. 2017 Apr 21;6(6):e1320011
pubmed: 28680754
Trends Mol Med. 2013 Jun;19(6):355-67
pubmed: 23601906